Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04364581
Other study ID # MS.19.06.685.R1.R2
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date May 1, 2020
Est. completion date May 1, 2021

Study information

Verified date April 2020
Source Mansoura University
Contact Mohamed S Abdelhafez, MD
Phone +201144523366
Email msabdelhafez@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate the effectiveness of short course of letrozole for endometrial preparation before hysteroscopic surgery for intracavitary lesions.


Description:

In the cycle subsequent to hysteroscopic identification of an endouteine pathology, patients who fitted with the inclusion criteria will be randomly divided into two groups; letrozole group (study group) and placebo group (control group). The randomization will be a stratified randomization with permuted blocking (the block size is randomly permuted among 2, 4, and 6) within each stratum. The only stratification variable will be by type of endouterine pathology. The randomization will be balanced (using a 1:1 treatment ratio) and will be carried out by a nurse through sealed, unlabeled, opaque envelopes containing computer-generated random numbers. The study will be double-blind (the participants, caregivers and investigators will be blinded to block size and group assignment).

Women in the letrozole group will be treated with letrozole (5 mg daily) for 10 days before hysteroscopic intervention while women in the placebo group will be treated with placebo for 10 days before hysteroscopic intervention in the early follicular phase of a natural cycle. In both groups, monopolar hysteroscopic surgery with glycine (1.5%) as uterine distension media will be used. Precise records of the duration of each surgical procedure, from the insertion to the removal of the resectoscope will be done.

Measurements of inflow, outflow, and amount of distension liquid absorbed by the patient will be taken meticulously. Intraoperative bleeding will be defined as "light" when bleeding does not interfere with surgery, "moderate" when bleeding required the coagulation of vessels, and "severe" when hemorrhage required immediate suspension of hysteroscopy. At the end of surgery, surgeon satisfaction with endometrial preparation using Visual Analogue Scale (VAS) and quality of visualization of the uterine cavity will be compared. Postoperative complications will be defined as the appearance of any complications occurring from the termination of the surgery to discharge.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date May 1, 2021
Est. primary completion date May 1, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Patients with endouterine pathologies, identified by office diagnostic hysteroscopy during the early endometrial proliferative phase (cycle days 7 to 8)

Exclusion Criteria:

- Presence of large submucous (type I, type II) or endocavitary (type 0) fibroids (according to the European Society of Hysteroscopy Classification of Submucous Fibroids) with a diameter exceeding 4 cm, for which preoperative treatment with GnRH agonists is indicated.

- Hormonal therapies in the previous 8 weeks (including the drug of the study).

- Uterine and/or concomitant adnexal pathologies (including malignancy) for which hysteroscopic surgery was not considered either safe or the method to resolve the problem.

- Cardiovascular, hepatic, or renal impairment.

- Allergy to letrozole.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Letrozole
Women will be treated with letrozole (5 mg daily) for 10 days before hysteroscopic intervention
Placebo
Women will be treated with placebo for 10 days before hysteroscopic intervention

Locations

Country Name City State
Egypt Mansoura University Hospital Mansoura Dakahlia

Sponsors (1)

Lead Sponsor Collaborator
Mansoura University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Operative time Time from start to end of the procedure Until 2 hours from the start of operation
See also
  Status Clinical Trial Phase
Recruiting NCT04519593 - ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma N/A
Active, not recruiting NCT06114758 - Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy
Not yet recruiting NCT05932082 - The Impact of Myomectomy on IVF Outcomes N/A
Not yet recruiting NCT05967936 - Paracervical Block Versus Transcervical Block in Outpatient Procedural Hysteroscopy N/A
Recruiting NCT04748978 - OPPIuM Technique and Myolysis With Diode Laser Dwls N/A
Recruiting NCT05271981 - Fertility After Uterine Artery Embolization
Completed NCT05025410 - Remimazolam and Remifentanil Without Neuromuscular Blocking Agent
Recruiting NCT03483142 - the Effect of Misoprostol on Intra-operative Blood Loss During Myomectomy Operation Phase 3
Completed NCT03533907 - Pregnancy Outcomes in Infertile Patients After Treatment With Ulipristal Acetate.
Completed NCT05811286 - The Use of a Morcellator in Operative Hysteroscopy for Benign Intracavitary Lesions: a Feasibility Study N/A
Not yet recruiting NCT03570879 - Laparoscopic Myomectomy With Morcellation or Transvaginal Extraction of Surgical Specimens.
Recruiting NCT06067971 - Evaluation of the Feasibility of Using Augmented Reality in Laparoscopic Surgery, by a Clinical Study During Gynecological Laparoscopic Surgical Procedures. (ENDORA2) N/A
Recruiting NCT04990076 - Ultrasound Evaluation of the Myometrium Using the MUSA Terminology Comparison With Histology
Recruiting NCT06325501 - Misoprostol Versus Oxytocin Infusion On Reducing Blood Loss During Abdominal Myomectomy Phase 3
Completed NCT05761418 - Preoperative Vaginal Dinoprostone Versus Misoprostone in Abdominal Myomectomy Phase 3
Recruiting NCT04311073 - Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies Phase 3
Active, not recruiting NCT05930769 - Retrospective Study on the Evaluation of the Impact of Augmented Reality Usage in Gynecological Laparoscopy on Patients Operated Between 2017 and 2021 (ImpactRA)
Recruiting NCT03550703 - Open Label Immunotherapy of Myoma Phase 2
Completed NCT04482959 - Intraoperative Carbetocin to Decrease Blood Loss During Hysteroscopic Myomectomy Phase 4
Not yet recruiting NCT04030273 - Prevalence of Intrauterine Adhesions After Abdominal Myomectomy